NHO Revive plans expanded access for Daraxonrasib in stage 4 pancreatic cancer

NHO Revive says it will open an Expanded Access Protocol next week to give eligible stage 4 pancreatic cancer patients pre-approval access to Daraxonrasib. The program could give patients without trial options another treatment path while FDA review continues.

Why it matters: - The Expanded Access Protocol could give some patients with stage 4 pancreatic cancer access to Daraxonrasib before FDA approval. - The program is aimed at patients who cannot tolerate current treatment or whose disease has progressed, creating another option when standard care is no longer working. - Expanded access programs can help bridge the gap between clinical development and regulatory approval for patients with serious illness.

What happened: - NHO Revive announced an Expanded Access Protocol for Daraxonrasib that is expected to begin next week. - The program will accept referrals from healthcare providers and inquiries from patients once it is active. - Eligibility is limited to stage 4 pancreatic cancer patients who meet the protocol criteria and are determined eligible by their treating physician. - Access will continue until Daraxonrasib receives FDA approval or the protocol is discontinued.

The details: - Daraxonrasib remains an investigational therapy and has not been approved by the FDA. - Expanded access, also called compassionate use, is intended for patients with serious or life-threatening conditions who may not qualify for an ongoing clinical trial. - Patients interested in the program can contact NHO Revive for eligibility information. - NHO Revive describes itself as a joint initiative between Nebraska Hematology Oncology and Revive Research Institute. - More information is available on the company’s website. - Nebraska Hematology-Oncology says it has served Lincoln and surrounding communities since 1997. - Nebraska Hematology-Oncology says the clinic has seven physicians, 13 advanced practice providers and more than 145 staff. - Nebraska Hematology-Oncology says it was the first QOPI-certified and Oncology Medical Home APC4-certified clinic in Nebraska.

Between the lines: - The announcement positions NHO Revive as a channel for patients who are running out of standard treatment options while Daraxonrasib remains under regulatory review. - The effort also highlights how research groups and oncology practices can use expanded access to respond to unmet need outside formal trials. - The physician quote frames the program as part of a broader push to provide treatment opportunities while the approval process continues.

What's next: - NHO Revive plans to begin accepting referrals and patient inquiries when the protocol goes live next week. - Physicians will play a central role in determining which patients qualify. - Daraxonrasib will remain available through the program only until FDA approval or protocol termination. - Patients and physicians seeking eligibility details are encouraged to contact NHO Revive.